SDZ 224-015

Overview

SDZ 224-015 is an orally active inhibitor of the interleukin-1 beta (IL-1β) converting enzyme and caspase-1 . SDZ 224-015 possesses anti-COVID-19 activity, targeting M pro (IC 50 of 30 nM).

Application

Products | Products > Disease Areas > Inflammation or Immune System Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Viral Infection | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Infection | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Immunology/Inflammation | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > Anti-infection | Products > Research Areas > Inflammation/Immunology | Products > Research Areas > Infection | Products > Signaling Pathways > Interleukin Related | Products > Signaling Pathways > Caspase | Products > Signaling Pathways > SARS-CoV

Product Information

• Catalog No.: HY-141622
• CAS No.: 161511-45-1
• Molecular Formula: C30H35Cl2N3O9
• Molecular Weight: 652.52
• Purity: 96.05%
• Storage: -20°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
• Solubility: ≥ 2.5 mg/mL (3.83 mM); Clear solution
• Availability: In-stock

Source

Original product source